Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms (CHIME)
Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms: Randomized Controlled Trial (CHIME Trial)
The goal of this clinical trial is to find out if calisda, a digital health intervention, can help women with menopause symptoms manage their symptoms and improve their quality of life.
The main questions it aims to answer are:
- Does calisda, together with regular treatment, improve health outcomes after six months better than regular treatment alone?
- Are the positive effects of calisda already noticeable after three months?
Researchers will compare two groups:
- Intervention group: Participants use the calisda intervention and continue their usual treatment.
- Control group: Participants continue with their usual treatment only.
Participants will:
- Fill out questionnaires online at the start of the study, after 3 months, and after 6 months
- Continue with their usual treatment (both groups) and use calisda, a digital health intervention, for six months (intervention group only)
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This pragmatic, two-arm randomized controlled trial evaluates the effectiveness of calisda, a certified medical device (CE-marked, risk class I), when used alongside regular treatment. The study compares the addition of this digital health intervention to treatment as usual (TAU) against TAU alone. Designed as an interactive online program, calisda incorporates recognized elements of cognitive behavioral therapy (CBT), behavior change, and patient education.
After confirming eligibility, participants are randomly assigned to one of two groups. The intervention group receives immediate access to calisda for six months alongside their usual treatment. The control group continues their regular treatment and is granted access to the intervention after a six-month waiting period.
Data is collected from both groups via online questionnaires at the start of the study, after three months, and after six months. The primary evaluation of effectiveness will be conducted at the six-month follow-up. Data collected at the three-month mark will be utilized to assess early treatment response.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Anja Specht, MSc.
- Telefonnummer: +49 40 3510520
- E-Mail: anja.specht@gaia-group.com
Studieren Sie die Kontaktsicherung
- Name: Clara Ekerdt, PhD
- Telefonnummer: +49 40 351052 135
- E-Mail: clara.ekerdt@gaia-group.com
Studienorte
-
-
-
Hamburg, Deutschland
- GAIA AG
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Female biological sex
- Age 40-65 years
- Diagnosis of menopause symptoms (ICD-10 code: N95.1) confirmed by a medical document
- Increased levels of menopause symptoms (MRS-II total score ≥ 14)
- Reduced menopause-specific quality of life (MENQOL total score ≥ 3)
- Stable symptom-related treatment (medication, psychotherapy, no treatment, …) for at least 60 days at the time of inclusion
- Sufficient knowledge of the German language
- Basic computer skills required for independent use of a digital intervention
- Consent to participation
Exclusion Criteria:
- Plans to change symptom-related treatment (medication, psychotherapy, …) in the upcoming 6 months after inclusion
- Current or history of any malignancy except for basal and squamous cell skin tumors
- Current HRT use
- Premature, medically induced menopause (e.g. following bilateral oophorectomy)
- Known somatic or psychiatric condition that might interfere with successful study participation (e.g. unstable neurologic or psychiatric disorder)
- Previous use of a digital intervention for menopause symptoms (including calisda) or another digital intervention developed by GAIA.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: calisda
Participants will receive access to the digital health intervention calisda in addition to TAU. |
Participants allocated to the intervention group will receive access to calisda in addition to treatment as usual (TAU). calisda is a digital health intervention designed for women with menopause symptoms, accessible through a web browser. The program focuses on treatment methods derived from cognitive behavioral therapy (CBT), health behavior change, and patient education. Topics addressed by calisda include understanding menopausal changes and symptoms, coping with hot flashes and night sweats, sleep, mood, self-acceptance and self-worth, relationship communication, as well as information on hormone therapy and complementary approaches. The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their progress. Once registered, the program remains accessible for six months. |
|
Kein Eingriff: Control group
Participants allocated to the control group will receive access to treatment as usual (TAU). |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
29-item Menopause-Specific Quality of Life Questionnaire (MENQOL; 1-week recall) total score
Zeitfenster: 6 months
|
The MENQOL is a patient-reported outcome measure (PROM) with 29 items. Each item uses a two-stage response format. This questionnaire consists of four domains, with varying item numbers: "vasomotor", "psychosocial", "physical" and "sexual". To obtain the total score, the mean of the domain scores is computed. Both the domain and the total scores range from 1 to 8. Higher total scores indicate greater impairment of quality of life. |
6 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Hot Flash Related Daily Interference Scale (HFRDIS) total score
Zeitfenster: 6 months
|
The HFRDIS is a 10-item PROM assessing the extent to which hot flashes interfere with daily activities and overall quality of life over the past week. Each item is rated from 0 ("did not interfere") to 10 ("completely interfere"). The total score is the mean of all items and ranges from 0 to 10. Higher total scores indicate greater hot flash interference and thus a worse outcome, whereas lower scores indicate less interference and a better outcome. |
6 months
|
|
Insomnia Severity Index (ISI) total score
Zeitfenster: 6 months
|
The ISI is a 7-item PROM assessing the nature, severity, and impact of insomnia. Each item is rated on a 5-point scale from 0 to 4. The total score is the sum of all items and ranges from 0 to 28. Higher total scores indicate greater insomnia severity and thus a worse outcome, whereas lower scores indicate less insomnia severity and a better outcome. |
6 months
|
|
Patient Health Questionnaire (PHQ-9) total score
Zeitfenster: 6 months
|
The PHQ-9 is a 9-item PROM assessing the severity of depressive symptoms. Each item is scored from 0 ("not at all") to 3 ("nearly every day"). The total score is the sum of all items and ranges from 0 to 27. Higher total scores indicate greater depressive symptom severity and thus a worse outcome, whereas lower scores indicate less severity and a better outcome. |
6 months
|
|
Menopause Rating Scale II (MRS-II) total score
Zeitfenster: 6 months
|
The MRS-II is an 11-item PROM assessing the severity of menopause-related symptoms. Each item is rated from 0 ("no complaints") to 4 ("very severe symptoms"). The total score is the sum of all items and ranges from 0 to 44. Higher total scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate less severity and a better outcome. |
6 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Philipp Klein, Prof. Dr. med., Universität zu Lübeck, Zentrum für Integrative Psychiatrie ZiP gGmbH
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- calisda RCT 2026
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .